Summary:
More clinically relevant models are urgently needed for preclinical drug development. This webinar discusses the development and characterization of HUB Organoid models to study and advance therapeutics for oncology, and immuno-oncology. The speakers describe HUB Organoid features that preserve the genetic and phenotypic characteristics of the original tumor, and provide insight into the unique high-throughput, high content imaging-based in vitro system for screening the efficacy of (immuno)oncological drugs and exemplify the use of the system to prioritize cancer drug candidates to enter the clinic.

Learning Objectives:

• Features and advantages of HUB Organoids™
• Why HUB Organoids are considered to be superior 3D preclinical model systems
• How to apply HUB Organoids to fundamental research and infectious diseases
• Impact and possibilities of HUB Organoids in oncology and immuno-oncology drug discovery

Who Should Attend:

• Drug developers interested in understanding the benefit of (tumor) organoids compared to standard 3D systems
• Decision makers from biotech and pharmaceutical companies who are looking to enhance the translatability of their early stage drug development programs
• Researchers interested in learning about HUB Organoids and their predictive power
• Biotech and pharma companies interested in high-throughput, high content imaging-based in vitro system for screening the efficacy of (immuno)oncological drugs

Speakers:

Robert Vries, PhD
CEO, Hubrecht Organoid Technology (HUB)

Robert Vries received his PhD in Biochemistry from the Leiden University Center on a molecular study of oncogenic transformation. He continued his scientific career as Postdoc at Stanford University (USA). Upon his return to the Netherlands, he joined the group of Hans Clevers at the Hubrecht Institute studying adult stem cells. In the group of Hans Clevers, he was part of the team that developed the ground-breaking technology that allowed the expansion of adult stem cells in vitro. The so-called Organoid Technology became the basis of the company Hubrecht Organoid Technology (HUB) of which he is currently the CEO.